Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03904550 · ClinicalTrials.gov registry record · Phase 2
Neuromuscular Blockade in Patients With Severe Renal Impairment
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03904550 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 49 participants.
The verdict
NCT03904550, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is intended to be a single-site, prospective, randomized, double-blinded study that intends to enroll a total of 60 patients with severe renal impairment undergoing surgery with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to receive either neostigmine (for reversal of cisatracurium) or sugammadex (for reversal of rocuronium). A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. All patients will be monitored with continuous pulse oximetry postoperatively for 24 hours.
Interventions
- DRUG Cisatracurium + Neostigmine
- DRUG Rocuronium + Sugammadex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03904550
The ClinicalTrials.gov registry entry for NCT03904550 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisatracurium + Neostigmine is the first listed.
NCT03904550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03904550 about?
NCT03904550 is a clinical study titled "Neuromuscular Blockade in Patients With Severe Renal Impairment". This study is intended to be a single-site, prospective, randomized, double-blinded study that intends to enroll a total of 60 patients with severe renal impairment undergoing surgery with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to receive either neostigmine...
What is the current status of trial NCT03904550?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2019-12-10. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT03904550?
The interventions under investigation include: Cisatracurium + Neostigmine (DRUG), Rocuronium + Sugammadex (DRUG).
Who is sponsoring clinical trial NCT03904550?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.